Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804647 | 0.95 | BACE1 (0.51) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL29674783 | 0.95 | OPRM1 (0.53) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL30299009 | 0.95 | OPRM1 (0.55) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL29804763 | 0.94 | OPRM1 (0.57) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL30477365 | 0.93 | OPRD1 (0.58) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL30376274 | 0.92 | OPRD1 (0.54) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL29375389 | 0.92 | BACE1 (0.56) | BACE1OPRM1OPRD1BACE2CTSD | |
| SCHEMBL29375740 | 0.92 | BACE1 (0.56) | BACE1OPRM1OPRD1BACE2CTSD | |
| SCHEMBL29436306 | 0.91 | OPRM1 (0.54) | BACE1OPRM1OPRD1BACE2OPRK1 | |
| SCHEMBL29375819 | 0.91 | OPRM1 (0.54) | BACE1OPRM1OPRD1BACE2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | claimed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | claimed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | claimed |
| EP-4593864-A1 | METHODS FOR TREATING OBESITY | Zealand Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| WO-2024068848-A1 | METHODS FOR TREATING OBESITY | ZEALAND PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| US-11814417-B2 | GIP agonist compounds and methods | ZEALAND PHARMA A/S (DK) | 2023-11-14 | — | — | US | disclosed |
| EP-4144362-A1 | COMPOSITIONS COMPRISING SHORT-ACTING HORMONES FOR TREATING OR PREVENTING OBESITY AND PUMPS COMPRISING SAID COMPOSITION | Adocia (FR) | 2023-03-08 | — | — | EP | disclosed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209054-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | BACE1 3779/4885OPRM1 1117/4885OPRD1 1008/4885 |
| US-11814417-B2 | GIP agonist compounds and methods | GIPR, GLP1R, GPR119 | BACE1 3779/4885OPRM1 1117/4885OPRD1 1008/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | BACE1 3779/4885OPRM1 1117/4885OPRD1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.